Table 5.
Characteristics of Postoperative COVID-19 Patients (n = 6)
| Patient | Sex, Age |
Tobacco Use | Medical History | Preoperative FEV1 | Subtype, cTNM |
Surgery, Approach, Date (dd/mm) |
pTNM, Resection |
MDM Decision |
|---|---|---|---|---|---|---|---|---|
| 1 | F 58 y |
Weaned | Arthritis/CS | 81% | Adk cT3N0M0 |
LUL Lobectomy RATS 14/03 |
pT2bN0M0 R0 |
Adjuvant CTX postponed due to COVID |
| 2 | M 66 y |
Weaned | IHD/ACE Arthritis/CS + IS |
77% | SCC cT1cN0M0 |
RLL Wedge VATS 16/03 |
pT1bN0M0 R0 |
No adjuvant treatment |
| 3 | M 66 y |
Active | Diabetes/ACE | 84% | Adk cT1bN0M0 |
LUL Lobectomy RATS 16/03 |
pT2N1M0 R0 |
Adjuvant CTX performed |
| 4 | F 69 y |
No | No | 114% | Adk cT1bN0M0 |
RUL Lobectomy VATS 23/03 |
pT1bN0M0 R0 |
No adjuvant treatment |
| 5 | M 70 y |
Weaned | Diabetes IHD COPD |
39% | Adk cT3N2M0 Induction CTX |
RUL lobectomy+SVC Open 30/03 |
pT3N2M0 R0 |
No adjuvant treatment |
| 6 | M 68 y |
Weaned | COPD | 62% | SCC cT2bN0M0 |
LUL lobectomy RATS 02/04 |
pT3N0M0 R0 |
Adjuvant CTX cancelled due to COVID |
ACE, angiotensin converting enzyme inhibitor; Adk, adenocarcinoma; COPD, chronic obstructive pulmonary disease; CS, corticosteroids; CTX, chemotherapy; F, female; IHD, ischemic heart disease; IS, immunosuppression; LUL, left upper lobe; M, male; MDM, multidisciplinary meeting; RATS, robot assisted thoracic surgery; RLL, right lower lobe; RUL, right upper lobe; SCC, squamous cell carcinoma; SVC, superior vena cava; VATS, video assisted thoracic surgery.